Back to News
Market Impact: 0.1
WuXi XDC Out-Licenses WuXiTecan-2 Payload-Linker Technology Platform to Ona Therapeutics to Advance Novel ADC Research and Development
Source: PR Newswire
Healthcare & Biotech
WuXi XDC Cayman Inc. (2268.HK), a global CRDMO focused on antibody-drug conjugates and other bioconjugates, issued a PRNewswire announcement from Shanghai on Sept. 17, 2026. The supplied article text is truncated before the substance of the announcement, so no financial, operational, or market-moving details can be assessed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- Jana Partners pushes Cooper to replace CEO, weigh asset sales- WSJ
- Halozyme prices $1.3 billion convertible notes offering
- FDA approves Ultragenyx’s Fayuvi for Sanfilippo syndrome Type A
- Why is Xenon Pharmaceuticals stock plunging today?
- Intel and Micron lead our portfolio higher, and J&J's strengthens our case for owning it
- Ultragenyx stock surges 10% on FDA approval for gene therapy
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- What Exactly Does Post-Training in LLMs and Finance-Focused AI Actually Mean for Asset Managers?
- What Is a Financial Ontology?